SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Anavex Life Sciences
AVXL 3.685-3.7%Dec 2 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: ImGettingBetter5/23/2022 10:47:25 AM
   of 120
 
On June 21 Anavex will host "R&D Day", at which the company will present updates to its clinical development pipeline.

Expected topics:

1. Confirm the ph3 Alzhiemer's disease clinical trial is completed, and the data is being compiled and reviewed in preparation for presenting the top line results (possibly on Sept 21 - World Alzheimer's Day)

2. Confirm the Parkinson's disease dementia (PDD) ph2 open label extension study is complete, and that the data is under analysis for top line release. Also indicate PDD and Parkinson's disease treatment next steps.

3. Confirm the M.J Fox-sponsored Parkinson's disease imaging study is designed and ready for enrollment. This study is intended to determine absorption and distribution details of orally administered Blarcamesine needed by neurons affected by Parkinson's disease.

4. Indicate plans for filing Blarcamesine NDAs to treat Rett syndrome in adults and pediatric patients.

5. Indicate plans for Fragile-X, FTD, A3-71 Alz trials.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News